<DOC>
	<DOC>NCT00635778</DOC>
	<brief_summary>This study will look for the highest tolerated dose of MK-0646 when given as a every other week infusion in patients with advanced solid tumors.</brief_summary>
	<brief_title>Infusion of MK-0646 in Subjects With Advanced Solid Tumors (MK-0646-002)(COMPLETED)</brief_title>
	<detailed_description>Trial Duration of Treatment : Patients will receive study drug for about 12 weeks. Patients may be able to receive MK-0646 for as long as 1 year if it seems to be stopping the growth of their cancer and not causing bad side effects. If the patient has a complete response to MK-0646, they may receive up to 8 additional weeks of treatment.</detailed_description>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Males and females with advanced solid tumors who have failed to respond to standard therapy, ages 18 years and older, with adequate organ function Patient is using growth hormones or growth hormone inhibitors Patient is known to be allergic to components of the drug or similar drugs (e.g. monoclonal antibodies such as rituximab or biological therapies such as immunoglobulin G Patient has had chemotherapy, radiotherapy, or biological therapy within 4 6 weeks of entering the study or has not recovered from previous therapy Patient is taking part in or has taken part in a study of an investigational compound or device within 30 days of their first dose of study drug Patient has an active Central Nervous System metastases and/or carcinomatous meningitis. However, a patient who has completed a course of therapy and is clinically stable may be able to participate Patient is pregnant or breastfeeding Patient is human immunodeficiency virus (HIV) positive Patient has a history of Hepatitis B or C Patient has symptomatic ascites or pleural effusion. However, if the patient has received treatment and is stable, they may be able to participate Female patient plans to become pregnant or a male patient who plans to impregnate their partner during the time the study is on going</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>